Equity Index Funds Very High Risk
The objective of the Scheme is to invest in companies whose securities are included in Nifty Pharma Index and subject to tracking errors, to endeavor to achieve the returns of the above index. This would be done by investing in all the stocks comprising the Nifty Pharma Index in the same weightage that they represent in Nifty Pharma Index. However, there is no assurance or guarantee that the investment objective of the scheme shall be achieved.
Expert-managed portfolios tailored to your financial goals.
Estimation is based on the past performance
| Index Funds | 1M | 3M | 6M | 9M | 1Y | 2Y | 3Y | 4Y | 5Y | 10Y | ALL |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Fund returns | 2.88% | 5.17% | 5.4% | 10.06% | 11.67% | 11.67% | 22.5% | 0% | 0% | 0% | 19.07% |
| Category returns | -0.65% | 1.06% | -3.74% | 0.35% | -0.44% | 3.46% | 15.62% | 15.56% | 13.29% | 12.1% | N/A |
| Absolute returns | 2.88% | 5.17% | 5.4% | 10.06% | 11.67% | 24.7% | 83.91% | 0% | 0% | 0% | 83.47% |
| Rank within category | 7 | 35 | 15 | 17 | 19 | 6 | 5 | 35 | 16 | 2 | N/A |
| Total Schemes in Category | 199 | 196 | 186 | 181 | 163 | 90 | 59 | 34 | 15 | 1 | N/A |
| Index Funds | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Yearly returns | N/A | 31.93% | 37.98% | -3.17% | 6.51% |
| Q1 returns | N/A | -4.58% | 12.7% | -9.66% | -2.23% |
| Q2 returns | N/A | 13.7% | 3.45% | 4.15% | 8.94% |
| Q3 Returns | N/A | 11.86% | 18.06% | -2.6% | N/A |
| Q4 Returns | N/A | 8.7% | 0.25% | 5.66% | N/A |
Expense ratio: 0.89%
Inclusive of GST
Exit load
Nil
| Alpha | -0.112838 |
| Beta | 0.9909 |
| Sharpe Ratio | 0.340285 |
| Sortino Ratio | 0.779449 |
| R-Squared | 0.9967 |
| Tracking Error | 0.1133 |
| Downside Risk | 16.4536 |
| Std. Deviation (Annualised) | 14.8824 |
| Index Funds | 1M | 3M | 6M | 9M | 1Y | 3Y | 5Y | 10Y | ALL | Fund Size (Cr) | Expense Ratio | Sharpe | Risk |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICICI Prudential NASDAQ 100 Index Fund - Growth | 3.4% | 20.34% | 19.26% | 31.71% | 48.5% | 31.45% | 0% | 0% | 20.28% | 3,254.80 | 0.90 | 0.42 | Very High |
| UTI Nifty 500 Value 50 Index Fund - Regular Plan - Growth | -0.78% | 0.5% | 10.6% | 18.03% | 19.66% | 30.59% | 0% | 0% | 30.25% | 750.31 | 1.14 | 0.38 | Very High |
| Motilal Oswal BSE Enhanced Value Index Fund - Regular Plan - Growth | -0.12% | -4.57% | 3.55% | 15.14% | 13.65% | 29.88% | 0% | 0% | 30.8% | 2,101.87 | 1.30 | 0.34 | Very High |
| Motilal Oswal S&P 500 Index Fund - Regular Plan - Growth | 1.37% | 11.96% | 13.28% | 22.32% | 37.16% | 25.21% | 17.78% | 0% | 20.49% | 4,365.10 | 1.06 | 0.44 | Very High |
| ICICI Prudential Nifty Pharma Index Fund - Regular Plan - Growth Current | 2.88% | 5.17% | 5.4% | 10.06% | 11.67% | 22.5% | 0% | 0% | 19.07% | 113.44 | 0.89 | 0.34 | Very High |
| Aditya Birla Sun Life Nifty Smallcap 50 Index Fund - Regular Plan - Growth | 0.04% | 9.21% | 3.46% | 4.48% | 0.34% | 22.44% | 12.76% | 0% | 15.54% | 312.17 | 0.88 | 0.26 | Very High |
| Kotak Nifty Smallcap 50 Index Fund - Regular Plan - Growth | 0.04% | 8.89% | 3.22% | 4.21% | 0.07% | 22.39% | 0% | 0% | 25.28% | 200.08 | 0.78 | 0.26 | Very High |
| Axis Nifty Smallcap 50 Index Fund - Regular Plan - Growth | 0.01% | 9.14% | 3.39% | 4.4% | 0.26% | 22.29% | 0% | 0% | 15.38% | 615.46 | 1.05 | 0.25 | Very High |
| ICICI Prudential Nifty Auto Index Fund - Regular Plan - Growth | 0.03% | -4.35% | -6.39% | -0.91% | 12.37% | 21.37% | 0% | 0% | 21.94% | 215.31 | 0.84 | 0.28 | Very High |
| Navi Nifty India Manufacturing Index Fund - Regular Plan - Growth | 0.14% | 1.53% | 3.25% | 6.83% | 10.64% | 20.64% | 0% | 0% | 17.78% | 75.71 | 0.90 | 0.30 | Very High |
| Instrument Allocation | Instrument | Assets % |
|---|---|---|
|
|
Domestic Equities | 99.94% |
| Cash & Cash Equivalents and Net Assets | 0.06% |
| Sector Allocation | Sector | Assets % |
|---|---|---|
| Pharmaceuticals & Biotechnology | 99.94% | |
| Others | 0.06% |
| Name | Sector | Instrument | Assets % |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 22.53% |
| Divi's Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 9.72% |
| Dr. Reddy's Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 9.49% |
| Cipla Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 8.67% |
| Lupin Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 6.58% |
| Torrent Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 5.15% |
| Laurus Labs Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 5.04% |
| Aurobindo Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 4.57% |
| Glenmark Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 4.26% |
| Alkem Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.72% |
| Biocon Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.02% |
| Mankind Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.99% |
| Zydus Lifesciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.63% |
| Ipca Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.50% |
| JB Chemicals & Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.97% |
| Gland Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.64% |
| Abbott India Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.55% |
| Ajanta Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.40% |
| Wockhardt Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.36% |
| Piramal Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.18% |
| TREPS | Cash & Cash Equivalents and Net Assets | 0.65% | |
| Net Current Assets | Cash & Cash Equivalents and Net Assets | -0.60% | |
| Total | 100.00% |
AMC
RETURNS
It is an Open ended scheme that primarily invests in Index Funds.
The objective of the Scheme is to invest in companies whose securities are included in Nifty Pharma Index and subject to tracking errors, to endeavor to achieve the returns of the above index. This would be done by investing in all the stocks comprising the Nifty Pharma Index in the same weightage that they represent in Nifty Pharma Index. However, there is no assurance or guarantee that the investment objective of the scheme shall be achieved.
The scheme benchmark is the NIFTY PHARMA - TRI
It is classified as Very High Risk, suitable for investors with a Very High risk appetite.
Returns Delivered by the funds are as follows:
1-year: 11.67%
3-year: 22.5%
5-year: 0%
Top holdings include names such as:
The NAV is around ₹18.35 (approx.) for the ICICI Prudential Nifty Pharma Index Fund - Regular Plan - Growth.
The fund’s AUM is approximately ₹113 Cr.
The expense ratio for the Regular Plan is 0.89.
Nil.
Minimum SIP starts at ₹1000.
The minimum lump sum investment is ₹1000. Often platforms may require higher in practice, but the statutory minimum remains the same.
You can start a SIP through:
Broker/agent platform like Sharescart.
Enter KYC details, choose the Regular Growth option, set SIP amount/frequency, and submit.
Yes. You can modify your SIP amount or frequency anytime online through the Sharescart platform.
You can redeem online via the Sharescart platform — choose the scheme, select the amount/units, and submit. Proceeds are credited to your bank account.
The fund managers: Nishit Patel, Ashwini Shinde, Venus Ahuja
This fund is suitable for investors with a Very High risk tolerance.
Get personalized Portfolio Management Services designed to grow and protect your wealth.
ChatGPT
Claude
Perplexity
